by Melanie A. Senior
The Battle For the Bulging
Despite disappointments in the hunt for effective fat-busting drugs, this large and seemingly ever-growing market is encouraging companies to continue to rise to the challenge of a disease that is a host of interacting disorders.
More from R&D
More from Scrip
• By
Sector-specific tariffs, including on pharmaceuticals, could be announced as early as this week.
• By
The pact could be worth more than $2.6bn and adds to growing big pharma investment in the technology.
• By
Following the near-total dominance of IgG antibodies, the UK group is backing the potential of IgA and IgE-based therapies to transform cancer treatment with the purchase of US-headquartered TigaTx.